Emerald Health Therapeutics Inc. (“EHT”) (TSXV:EMH) (OTCQX:EMHTF)
is pleased to announce the appointment of Chris Wagner as Chief
Executive Officer and a director of EHT. Mr. Wagner has spent more
than 25 years in marketing pharmaceutical products and building
biotechnology companies. Bin Huang, PhD, will continue to focus on
the management of the company’s operations and expansion as
President of Emerald Health Botanicals (“Botanicals”), EHT’s wholly
owned subsidiary which is a Licensed Producer under the Canadian
Access to Cannabis for Medical Purposes Regulations.
“Mr. Wagner is an accomplished pharmaceutical
executive who has used his entrepreneurial, marketing, and
leadership skills to guide young life science companies to success.
We are pleased to have him join our team as CEO and a director,”
said Avtar Dhillon, MD, Chairman of EHT. “Chris’ expertise could
not be better suited to the opportunities represented by the
Canadian cannabis industry’s transition to legal adult use.
Combining his capabilities with Bin’s execution of Botanicals’
expansion plans strengthens our ability to achieve Emerald’s vision
to be a prominent player in this promising industry.”
Mr. Wagner worked with Eli Lilly for ten years,
rising to Global Team Leader and working in Europe, North America
and Asia. Mr. Wagner helped develop and commercialize 15 biologic
and small molecule products while at Lilly. He also worked on the
global marketing of several notable products, including Prozac®,
Cialis®, and Zyprexa®, which achieved annual sales of over $4
billion per year.
Mr. Wagner left Eli Lilly to join Aspreva
Pharmaceuticals Inc. as Vice President, Business Development and
Global Marketing, where he helped negotiate global alliances with
Roche and Chugai. Mr. Wagner joined Aspreva as its second employee
when its valuation was $2 million. During his five years at Aspreva
the company reached a valuation of $1 billion; it was later
acquired by Galenica.
Mr. Wagner most recently served as Chairman,
President and CEO of Contextual Genomics Inc, a molecular
bioinformatics company that has worked with AstraZeneca, Pfizer and
Sanofi to develop and commercialize genomic cancer diagnostic
products. He was previously Director, President and CEO of Sirius
Genomics Inc., a personalized genomic medicines company. While
building these companies, he led expert management and scientific
teams through strategy development, scientific discovery, product
development, intellectual property formulation, clinical and
regulatory processes, capital raising, licensing and partnership
deals.
Mr. Wagner is, or has served, on boards at BC
Children's Hospital, The Rick Hansen Institute, Canadian Gene Cure
Foundation, and LifeSciences BC. He has a BSc in organic chemistry
from the University of British Columbia and completed executive
programs in finance and marketing research at Wharton Business
School and Kellogg School of Management.
“Legalization of adult-use cannabis represents a
once-in-a-lifetime opportunity to help unveil and deliver the
benefits of this amazing plant,” said Mr. Wagner. “Emerald’s
leadership and management team have maintained the highest level of
federal compliance, scientific rigor, and focus on enhancing human
health. I am excited to lead and work with this team to advance
Emerald’s distinctive business strategy.”
“We welcome Chris to the Emerald team,” said Bin
Huang, PhD. “As Emerald scales to large-volume, low-cost production
to meet the cannabis demand expected in 2018 and beyond, Chris’
strategic guidance and notably his marketing and product
development expertise will be valuable in positioning Emerald for
growth in both the short and long term.”
Join us on our journey of making lives better through
cannabis science.
About Emerald Health Therapeutics Inc.
Emerald Health Therapeutics, Inc. (TSXV:EMH)
(OTCQX:EMHTF) operates primarily through Emerald Health Botanicals
Inc. ("Botanicals"), a wholly owned subsidiary and Licensed
Producer under the Access to Cannabis for Medical Purposes
Regulations. Botanicals is authorized to produce and sell both
dried medical cannabis flower and medical cannabis oil in Canada.
Botanicals currently operates an indoor facility in Victoria, BC,
and is progressing on expansion plans for a 32-acre property in
Metro Vancouver and a joint venture with Village Farms, called Pure
Sunfarms, utilizing a 25 acre existing greenhouse complex in Delta,
BC. Botanicals is one of Canada's most medically focused licensed
producers, with a team highly experienced in life sciences product
development and large-scale agribusiness. Its vision is to be a
leading provider of cannabis products through its production
capabilities, proprietary genetics, value-added products and
branding, and superb customer experience. Emerald Health
Therapeutics is part of the Emerald Health group, which comprises
multiple companies advancing diverse botanical, nutraceutical and
pharmaceutical products that may provide wellness and medical
benefits by interacting with the body’s endocannabinoid system.
For investor and media contacts:
invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Statements Regarding Forward
Looking Information
Certain statements in this press release
constitute forward-looking statements, within the meaning of
applicable securities laws. All statements that are not historical
facts, including without limitation, statements regarding future
estimates, plans, programs, forecasts, projections, objectives,
assumptions, expectations or beliefs of future performance, are
"forward-looking statements".
We caution you that such "forward-looking
statements" involve known and unknown risks and uncertainties that
could cause actual and future events to differ materially from
those anticipated in such statements.
Forward-looking statements include, but are not
limited to, statements with respect to legalization of
non-therapeutic cannabis sales in Canada; participation in the
legalized non-therapeutic cannabis industry; growth in the
extract-based market; increased production of cannabis; commercial
operations; construction or conversion of production facilities;
applications for licensing; obtaining such licenses; commencement
of production of cannabis at the Company’s facilities; estimates of
production capacity at such facilities; contributions of cash to
the JV; international opportunities for the Company; commencement
of clinical trials; the Company becoming a leading Canadian
supplier of cannabis products; expected timing of any of the above
matters; and other information that is based on forecasts of future
results, estimates of amounts not yet determinable and assumptions
of management.
Emerald Health Therapeutics Inc. does not
intend, and does not assume any obligation, to update these
forward-looking statements except as required by law. These
forward-looking statements involve risks and uncertainties relating
to, among other things, failure of the federal government to
approve legislation legalizing sales of non-therapeutic adult-use
cannabis; failure to obtain Health Canada and other regulatory
approvals; failure to obtain necessary financing; results of
production and sale activities; the Company's historical experience
with medical marijuana operations; results of scientific research;
uninsured risks; regulatory changes; difficulties in construction
or in obtaining qualified contractors to complete construction or
conversion of facilities; availability of production facilities;
timeliness of government approvals and the granting of permits and
licenses; changes in prices and costs; actual operating and
financial performance of facilities; equipment and processes
relative to specifications and expectations; as well as the other
risk factors set out in the Company’s annual information form and
other filing with the applicable Canadian securities regulators,
which may be viewed at www.sedar.com. Actual results may differ
materially from those expressed or implied by such forward-looking
statements.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Sep 2023 to Sep 2024